Characteristic patients, n | Values |
---|---|
Age, median [range] | 62 [46-76] years |
Preoperative PSA, median [range] | 16.7 [1-60] ng/ml |
pTNM stage, n (%) | |
pT2a | 2 (3.4) |
pT2b | 1 (1.7) |
pT2c | 22 (37.3) |
pT3a | 20 (33.9) |
pT3b | 14 (23.7) |
pN- | 47 (79.7) |
pN+ | 1 (1.7) |
pNx | 11 (18.6) |
Gleason score, n (%) | |
3–6 | 12 (20.3) |
7* | 30 (50.9) |
3+4 | 13 (23.6) |
4+3 | 13 (23.6) |
8 | 7 (11.9) |
9 | 10 (16.9) |
Positive surgical margins†, n (%) | 35/58 (60.3) |
Minimal <3 | 19/34 (55.9) |
Extensive ≥3 | 15/34 (44.1) |
Perineural invasion, n (%) | 40/46 (87) |
Detectable PSA after surgery, n (%) | 12 (20.3) |
PSA rise after postsurgical negativity, n (%) | 47 (79.7) |
PSA doubling time, median | 12.9 months |
PSA nadir preRT, median | 0.4 ng/ml |
PSA level preRT, median | 1.43 ng/ml |
Surgery to RT interval, median | 26 months |